Filing Flows › Vertex Pharmaceuticals (VRTX) › Q3 2026
Vertex Pharmaceuticals (VRTX) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 3, 2026
Vertex Pharmaceuticals (VRTX) reported revenue of $3.4B for the third quarter 2026 (Q3 2026), +12% from a year earlier and +3% from the quarter before. Operating margin was 20.7%, net earnings $654M (19.0% of revenue).
Vertex Pharmaceuticals, Q3 2026: revenue $3.4B (+12% year over year), operating margin 20.7%, net earnings $654M, operating cash flow $643M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.4B | +3% | +12% |
| Operating profit | $713M | -43% | -40% |
| Net earnings | $654M | -41% | -40% |
| Operating cash flow | $643M | -43% | -48% |
| Free cash flow | $546M | -46% | -52% |
What changed
Revenue was $3.4B in Q3 2026, up 12% year over year and up 3% from the previous quarter. TRIKAFTA/KAFTRIO was the largest line at 71% of revenue. ALYFTREK added $0.46B year over year (up 186%), 126% of the total change. TRIKAFTA/KAFTRIO declined 8%.
Operating profit was $0.71B, a 20.7% margin (down 17.8 points year over year). Operating profit fell $0.47B even though revenue rose $0.36B versus Q3 2025, so costs grew faster than sales. Total costs grew 44% against revenue growth of 12%. The fastest-growing cost line was SG&A (+90%). Net earnings were $0.65B, down 40% year over year. The effective tax rate was 16.6%.
Operating cash flow was $0.64B (down 48% year over year), 98% of net earnings. Non-cash charges added back $0.07B of depreciation and amortization and $0.17B of share-based compensation. Working capital and other items used $0.25B. Capital expenditures of $0.10B left free cash flow of $0.55B.
Questions
What was Vertex Pharmaceuticals' revenue in the third quarter 2026?
Vertex Pharmaceuticals (VRTX) reported revenue of $3.4B for the third quarter 2026 (Q3 2026), +12% from a year earlier and +3% from the quarter before.
Was Vertex Pharmaceuticals profitable in the third quarter 2026?
Operating profit was $713M (20.7% of revenue) and net earnings $654M.